BOULDER — Biodesix Inc. (Nasdaq: BDSX) has agreed to build a companion test for HiberCell Inc. as the latter takes its breast cancer drug candidates through clinical trials.
In a statement, the Boulder-based Biodesix said it and New York City-based HiberCell will co-develop the test to determine suitable candidates for HiberCell’s candidate treatments for hibernating or relapsed breast cancer.
Financial terms of the deal were not disclosed.
The collaboration marks Biodesix’s entry into developing tests for a new part of the body. The company historically has focused on developing tests that help doctors of lung cancer patients determine the best modes of treatment; last year it partnered with Bio-Rad Laboratories Inc. (NYSE: BIO) to launch COVID-19 active infection and antibody tests.
Biodesix CEO Scott Hutton also hinted that the two companies could make other assays for HiberCell treatment candidates. HiberCell’s focus is on treating hibernating cancer cells within patients in remission.
“Working together on a companion diagnostic for the [breast cancer treatment trial] program is only touching the surface of what we can do together,” he said. “This approach to identifying patients for this drug is very novel and holds tremendous promise.”
The announcement comes days after Biodesix said it expects to post revenues of $25 million to $27 million during the final quarter of 2020, a sharp increase from the $9.2 million it recorded in the quarter prior.
Those figures come months after Biodesix debuted on the Nasdaq Global Markets, raising $63 million after deducting underwriting costs and additional fees but missing its maximum fundraising target of $79 million.
© 2021 BizWest Media LLC
BOULDER — Biodesix Inc. (Nasdaq: BDSX) has agreed to build a companion test for HiberCell Inc. as the latter takes its breast cancer drug candidates through clinical trials.
In a statement, the Boulder-based Biodesix said it and New York City-based HiberCell will co-develop the test to determine suitable candidates for HiberCell’s candidate treatments for hibernating or relapsed breast cancer.
Financial terms of the deal were not disclosed.
The collaboration marks Biodesix’s entry into developing tests for a new part of the body. The company historically has focused on developing tests that help doctors of lung cancer patients determine the best modes of treatment; last year it partnered with Bio-Rad Laboratories Inc. (NYSE: BIO) to launch COVID-19 active infection and antibody tests.
Biodesix CEO Scott Hutton also hinted that the two companies could make other assays for HiberCell treatment candidates. HiberCell’s focus is on treating hibernating cancer cells within patients in remission.
“Working together on a companion diagnostic for the [breast cancer treatment trial] program is only touching the surface of what we can do together,” he said. “This approach to identifying patients for this drug is very novel and holds tremendous promise.”
The announcement comes days after Biodesix said it expects to post revenues of $25 million to $27 million during the final quarter of 2020, a sharp increase from the $9.2 million it recorded in the quarter prior.
Those figures come months after Biodesix debuted on the Nasdaq Global Markets, raising $63 million after deducting underwriting costs and additional fees but missing its…
This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.
Want to See More!?
OR
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Print + Digital
$7/mo
billed monthly
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
Digital
$7/mo
billed monthly
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
Unlimited
$25/mo
billed annually
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
Your promotional subscription will automatically renew at the full rate on the date of your subscription maturity. Reminder notices will be emailed before each auto-renewing payment to the email address on file. You may cancel at any time by calling (970) 232-3143 or emailing bdennis@bizwest.com. Your BizWest subscription also includes a complimentary subscription to the BizWest email newsletter, and you may easily unsubscribe from this at any time by emailing bdennis@bizwest.com.






